Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her "undeniable ability to negotiate new partnerships."

Yaccarino will be CEO of a unit at the Miami-based company, which focuses on patients taking weight-management medications.

Yaccarino has been named CEO of Miami-based eMed Population Health, which calls itself “the leading digital health platform for GLP-1/GIP population health management.” That refers to the class of weight-loss drugs like Wegovy and Ozempic.